Paras Biopharmaceuticals Finland Oy

PB (RA)-2010 (Biosimilar candidate to Kineret®)

• PB-RA-2010 is (originator soon to be off patent) a recombinant human Interleukin-I receptor-antagonist protein.
• PB-RA-2010 is a biosimilar candidate molecule that works by blocking the biological activity of the IL-I receptor. IL-I is a key mediator of inflammation and a driver of auto inflammatory diseases in both adults and children.
• PB-RA-2010 is a recombinant non-glycosylated version of IL-IRA produced in genetically modified E. Coli using recombinant DNA technology. It consists of 153 a.a.and possesses a molecular mass of 17.3 KDa.
• Paras Biopharmaceuticals Finland Oy has successfully achieved a very high expression of the Biosimilar Rheumatoid Arthritis candidate.

Kineret^® is a registered trademark of/marketed by Sobi/Amgen.